Global Recombinant Trypsin Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Recombinant Trypsin Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Recombinant trypsin is a genetically engineered version of the enzyme trypsin, which is involved in the digestion of proteins. Recombinant trypsin is produced through recombinant DNA technology, which involves inserting the gene for trypsin into a host organism, such as bacteria or yeast, and allowing the host organism to produce the enzyme.

Market Overview:

The latest research study on the global Recombinant Trypsin market finds that the global Recombinant Trypsin market reached a value of USD 25.68 million in 2022. It’s expected that the market will achieve USD 42.75 million by 2028, exhibiting a CAGR of 8.87% during the forecast period.

Insulin manufacturing has a high demand for recombinant trypsin

Diabetes is a global epidemic. One of the key goals of the Global Compact on Diabetes, launched by the World Health Organization in April 2021, is to increase the accessibility and affordability of the life-saving medicine insulin. According to relevant figures, before the emergence of COVID-19, more than 420 million people (6% of the world's population) had diabetes, and this number is expected to explode to 500 million by 2030. The increase in the number of diabetic patients worldwide will lead to a consequent increase in the need for insulin. Furthermore, there is an unmet need for affordable insulin, especially in low- and middle-income countries. Therefore, insulin has a large demand in the global market. Meanwhile, in insulin production, the C-peptide in proinsulin is enzymatically cleaved with recombinant trypsin to obtain active, correctly folded insulin. Therefore, recombinant trypsin is widely used in the manufacturing process of insulin.

In the global market, high demand for recombinant trypsin for insulin manufacturing is driving the industry.

Vaccine manufacturing has a high demand for recombinant trypsin

Recombinant trypsin has several advantages in vaccine manufacture. First of all, recombinant trypsin improves the safety of vaccines, because trypsin extracted from animals may contain exogenous risk substances such as pathogenic factors, animal viruses, prion proteins, etc., resulting in residues in the vaccine, while recombinant trypsin does not contain these Alien risk substances. Secondly, the yield is greatly improved, the production cost is reduced, and the threshold of separation and purification technology is lowered, so that it can be used in large-scale production and commercial application, and the enzyme cleavage specificity of the activated trypsin is consistent with the source of the animal pancreas. Finally, trypsin extracted from animals has a large difference between batches due to different animal sources, while the raw material of recombinant trypsin is stable, the product quality is stable, and the difference between batches is small. Hence, vaccine manufacturing has a high demand for recombinant trypsin, which is increasing the market share of the recombinant trypsin industry.

Region Overview:

In 2022, the share of the Recombinant Trypsin market in Europe stood at30.23%.

Company Overview:

Novozymes is one of the major players operating in the Recombinant Trypsin market, holding a share of 20.97% in 2023.

Novozymes and Biotalys announce successful Evoca™ feasibility study

October 25, 2022
Novozymes and Biotalys, an agricultural technology (AgTech) company protecting crops and food through protein-based biocontrol solutions, announced the successful results of a feasibility study for Evoca™*, Biotalys' first proprietary biocontrol candidate. Novozymes received proof of concept for a new manufacturing process with potentially significant cost-of-goods and scale advantages, expanding the commercial potential of Evoca as a novel biocide.
Evoca is Biotalys' first innovative protein-based biofungicide developed on the company's AGROBODY Foundry™ platform. Since the partnership was established in June 2022, Novozymes has explored additional avenues for the upscaling and production of Evoca bioactive proteins by using production hosts other than those currently used by Biotalys.

Segmentation Overview:

By type, Solid segment accounted for the largest share of market in 2022.

Application Overview:

The market's largest segment by application is the segment Insulin Manufacturing, with a market share of 50.04% in 2022.

Key Companies in the global Recombinant Trypsin market covered in Chapter 3:

Novozymes
Thermo Fisher
Roche
Biosera
Sartorius (Biological Industries)
Solarbio
BasalMedia
Merck
Yaxin Bio

In Chapter 4 and Chapter 14.2, on the basis of types, the Recombinant Trypsin market from 2018 to 2029 is primarily split into:

Solution
Solid

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Recombinant Trypsin market from 2018 to 2029 covers:

Insulin Manufacturing
Vaccines Manufacturing
Cell Culture

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)